An HIV prevention jab that provides six months of protection at a time was given the green light by South Africa’s medicines regulator. The approval helps to clear the way for a limited public sector rollout of the “game-changing” shot set to start in April 2026.
A new HIV prevention jab has the potential to bring an end to the AIDS epidemic. But a lack of ambition and unjustifiable secrecy over pricing is holding it back, argue three leading health activists.
An HIV prevention pill that could provide a month of protection per tablet has been given the green light to proceed to pivotal trials to test its efficacy. Elri Voigt reports on new findings on the pill that were presented at the International AIDS Conference.
Over the last two decades, South Africa made massive progress in reducing transmission of HIV from mothers to their babies. Even so, about 7 000 babies still contract the virus every year. Experts put this down to having the right puzzle pieces for prevention but failing to integrate them optimally. Elna Schütz reports.
Research led by Professor Adrie Bekker is paving the way for an important HIV medicine to be made available to neonates in a way that is both safe and much more convenient than previous options. Biénne Huisman met with the passionate clinician-scientist at her office in Cape Town.
Elzette Rousseau from the Desmond Tutu HIV Foundation told attendees at the top HIV conference in The United States about a project taking HIV prevention services to schools in Cape Town. Biénne Huisman visited one of the sites to find out how it works.
Ahead of World AIDS Day 2024, Professor Salim Abdool Karim and Dr Nikita Devnarain argue that South Africa needs a concerted effort to reduce new HIV infections in young women and to prepare for the rollout of long-acting forms of HIV prevention alongside a well-functioning HIV treatment programme.
Whether or not someone living with HIV in South Africa gets a one- or three-months’ supply of antiretrovirals at a time depends partly on the clinic where they happen to go for HIV care. Ahead of World AIDS Day 2024, Elri Voigt unpacks the legal and policy issues relating to prescriptions and HIV medicine refills and asks why people living with HIV are treated so differently in different parts of the country.
HIV prevention injections that can provide two, or even six, months of protection per shot have arguably been the biggest HIV story of the year. Ahead of World AIDS Day, Professor Francois Venter assesses the state of play and the critical next steps with these potentially game-changing new tools in the fight against HIV.
A new HIV prevention injection is now available to a select number of people in South Africa. That a single shot provides two months of protection is one of the injection’s major selling points. In this story, Elri Voigt unpacks how much of the jab is available, who is choosing to get it and what other anti-HIV drugs are being rolled out.
National Treasury has proposed a R1 billion cut to HIV funding. This has come about because – rather than seeing the reduced price of antiretroviral treatment as an opportunity to scale up treatment coverage and strengthen other interventions to address the HIV epidemic – the Department of Health has seen it as an opportunity for cost-containment. However, the HIV epidemic is not over and savings owing to cost reductions should not simply be returned to Treasury, argue Matshidiso Lencoasa and Mila Harding.
Researchers have been trying to develop antiretroviral medicines that can last for weeks, months or even years per dose. Two such long-acting formulations have been approved in South Africa, but several more are on the horizon. Elri Voigt explores the science behind what makes a formulation long-acting and takes a look at some particularly exciting prospects.
